| Literature DB >> 25227910 |
G Malcherek1, N Jin2, A G Hückelhoven1, J Mani1, L Wang1, U Gern1, A Diehlmann1, P Wuchter1, A Schmitt1, B Chen3, A D Ho1, M Schmitt1.
Abstract
Mesenchymal stromal cells (MSCs) possess broad immunomodulatory capacities that are currently investigated for potential clinical application in treating autoimmune disorders. Third-party MSCs suppress alloantigen-induced proliferation of peripheral blood mononuclear cells providing the rationale for clinical use in graft-versus-host disease (GvHD). We confirmed that MSCs strongly inhibited proliferation of CD8(+) T cells in a mixed lymphocyte reaction. However, MSCs also suppressed proliferation of T cells specifically recognizing cytomegalovirus (CMV) and influenza virus. Inhibition was dose dependent, but independent of the culture medium. MSCs inhibited proliferation of specific CD8(+) T cells and the release of IFN-γ by specific CD8(+) T cells for immunodominant HLA-A2- and HLA-B7- restricted antigen epitopes derived from CMV phosphoprotein 65 and influenza matrix protein. This is in contrast to a recently reported scenario where MSCs exert differential effects on alloantigen and virus-specific T cells potentially having an impact on surveillance and prophylaxis of patients treated by MSCs.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25227910 DOI: 10.1038/leu.2014.273
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528